공지 • Apr 21
Lobe Sciences Ltd. announced that it has received CAD 0.95 million in funding On April 20, 2026, Lobe Sciences Ltd. has closed the transaction. 공지 • Apr 08
Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026 Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026. Board Change • Jan 17
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Advisor Ilan Hayman is the most experienced director on the board, commencing their role in 2021. Independent Director Harry Jacobson was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공지 • Jan 14
Lobe Sciences Ltd Appoints Mr. Nick Karakochuk to Board of Directors Lobe Sciences Ltd. announced the appointment of Mr. Nick Karakochuk to its Board of Directors as the Company continues to build on the momentum established during fiscal 2025. Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He regularly advises public and private issuers on stock exchange requirements, securities regulatory compliance, and continuous disclosure obligations, and has extensive experience supporting companies through complex transactions and strategic growth initiatives. New Risk • Dec 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$9.43m market cap, or US$6.86m). 공지 • Sep 10
Lobe Sciences Ltd. Appoints Mr. Marco Mastrodonato to the Company's Board of Directors Lobe Sciences Ltd. announced the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and biotechnology industries. He was the former Co-Founder and Executive Director of Sinclair Pharma plc., a publicly listed pharmaceutical company on the London Stock Exchange. He founded and served as a Board Member of Metrodora Therapeutics Inc.; a U.S. biotechnology company focused on systemic inflammation and the treatment of anemia. Mr. Mastrodonato is also the Founder and CEO of BMG Pharma, where he leads the development and global commercialization of innovative hyaluronic acid-based technologies across aesthetic dermatology. ophthalmology and osteoarthritis. New Risk • Sep 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$11.9m market cap, or US$8.58m). New Risk • Aug 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (CA$9.08m market cap, or US$6.61m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). 공지 • Jul 29
Lobe Sciences Ltd. announced that it expects to receive CAD 0.341425 million in funding Lobe Sciences Ltd announced a non brokered private placement to issue 8,535,625 common shares at an issue price of CAD 0.04 for the proceeds of CAD 341,425 on July 29, 2025. All securities to be issued pursuant to the offering will be subject to a statutory four-month-and-one-day hold period. 공지 • Jan 15
Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025 Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025. New Risk • Dec 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$462k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$462k free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-CA$3.1m). Earnings have declined by 3.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (CA$136k revenue, or US$95k). Market cap is less than US$10m (CA$4.29m market cap, or US$2.98m). 공지 • Nov 19
Lobe Sciences Ltd. and Alera Pharma, Inc. Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™ Lobe Sciences Ltd. and Alera Pharma Inc. announced that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof. This application contains claims covering compositions comprising a psilocin mucate salt or conjugate and methods for their production and use in conditions treatable with psilocin. New Risk • Sep 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 117% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$1.1m). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (117% increase in shares outstanding). Revenue is less than US$1m (CA$977k revenue, or US$718k). Market cap is less than US$10m (CA$3.43m market cap, or US$2.52m). 공지 • Aug 16
Lobe Sciences, Ltd Announces Management Appointments to Alera Pharma, Inc Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera. 공지 • Jun 01
Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of Directors Lobe Sciences Ltd. announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancements in mental health and wellness. Dr. Sancilio completed his B.S., M.S., and Ph.D. in Physical and Analytical Chemistry at Rutgers, The State University of New Jersey. His career has been marked by significant achievements, including founding aaiPharma Inc., where he led the company to become the world's dosage form development company with over 1,000 US FDA and 500 European drug approvals. Dr. Sancilio has a proven track record of driving growth and innovation, having founded multiple successful pharmaceutical companies and contributed to the biopharmaceutical industry's development in North Carolina. As a serial entrepreneur Dr. Sancilio is largely responsible for helping to define the modern Contract Research and Development Organization marketplace with the founding of aaiPharma Inc. which focused on providing drug product development services to both entrepreneurial and established pharmaceutical companies. The company became a NASDAQ publicly traded company in 1996 and grew to a market capitalization of nearly $1BB by 2001. Dr. Sancilio retired from aaiPharma in June 2002. The company was reorganized in 2005, privatized and renamed Alcami Inc., and continues to dominate its business segment. Following his retirement as CEO of aaiPharma in 2002, Dr. Sancilio established a family office in Jupiter, Florida and affiliated with several investment and merchant banks in South Florida including Comvest Partners and the Noble Capital Markets. In 2007, he founded Sancilio & Company Inc. (SCI), a specialty pharmaceutical company located in Palm Beach County, Florida. SCI’s primary focus was to develop drug products for diseases with unmet medical needs. The Company’s 150,000 square foot facility in Riviera Beach, Fl was approved as a drug manufacturing site by the US FDA in 2017 and received its first prescription drug approval in that facility in early 2018 making it the first US FDA approval of a drug product in Palm Beach County in over 2 decades. Facilities, products and intellectual property were acquired in early 2018 and are now operated by Procaps Group SA, a NASDAQ listed Company. In early January 2018, Dr. Sancilio and his wife Carolyn Sancilio founded Clearway Global Inc., a consulting and product development company that is wholly owned by Sancilio & Company, located in Stuart, Fl. He continues to do research and development work in sickle cell disease, broad spectrum anti-viral drugs and neurological disorders including Alzheimer’s Disease, substance abuse and addiction. He is also involved in guiding the development of several new drug candidates for Clearway Global’s international client companies where he serves in a variety of positions. In July 2019, Dr. Sancilio accepted a position as a Research Professor and Managing Director, Translational Development & Commercialization in the Division of Research at Florida Atlantic University, Boca Raton, Fl and continues as a Research Professor in the Department of Chemistry and Biochemistry. 공지 • May 31
Harry Jacobson to Join the Board of Directors of Lobe Sciences Ltd Lobe Sciences Ltd. announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months. Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases. Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation’s premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC). As Vice Chancellor for Health Affairs, Dr. Jacobson’s 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt’s federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children’s Hospital and Vanderbilt Health at 100 Oaks. During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont’s Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017. 공지 • May 17
Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024 Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024. Location: british columbia, vancouver Canada New Risk • May 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$225k free cash flow). Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (CA$977k revenue, or US$714k). Market cap is less than US$10m (CA$3.29m market cap, or US$2.41m). Minor Risk Shareholders have been diluted in the past year (6.2% increase in shares outstanding). New Risk • May 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$225k free cash flow). Share price has been highly volatile over the past 3 months (45% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (CA$977k revenue, or US$710k). Market cap is less than US$10m (CA$4.81m market cap, or US$3.50m). New Risk • Mar 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 93% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Negative equity (-CA$160k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Revenue is less than US$1m (CA$841k revenue, or US$621k). Market cap is less than US$10m (CA$2.97m market cap, or US$2.19m). New Risk • Feb 16
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$160k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (46% average weekly change). Negative equity (-CA$160k). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (102% increase in shares outstanding). Revenue is less than US$1m (CA$841k revenue, or US$623k). Market cap is less than US$10m (CA$3.10m market cap, or US$2.30m). 공지 • Dec 07
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program Lobe Sciences Ltd. provided an update from the Company's lead clinical program, L-130, a proprietary stabilized psilocin conjjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. All subjects were dosed with no significant adverse events. The study confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable, capsule over its active prodrug, psilocybin. The mean maximum plasma concentration (Cmax) for L-130 was significantly higher than expected, demonstrating superior bioavailability compared to published literature of psilocybin. Additionally, time to achieve the maximum plasma concentration (Tmax) was lower for L-130 due to elimination of first-pass metabolism and immediate absorption in the gut. Full results are expected to be published in peer reviewed journals in the first half of 2024. Collectively, the superior pharmacokinetics of L- 130 offers significant therapeutic advantages over other psilocybin formulations as psilocybin itself is not biologically active in humans and must be converted into psilocin via dephosphorylation in the gut. By eliminating this first pass metabolism, industry experts believe the direct administration of psilocin may offer therapeutic benefits such as faster onset time, improved dosing consistency, increased bioavailability and importantly, the potential for reduced side effects. 공지 • Sep 19
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer Lobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia. 공지 • Jun 28
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130 Lobe Sciences Ltd. announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers. The first-in-man, open-label study, conducted in Jordan under the authority of the Jordan Food and Drug Administration, will help determine the dose range of L-130 for a planned Phase 2 trial targeting the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs). The Phase 1 study, conducted in compliance with the GCP and GLP regulatory requirements of the Declaration of Helsinki and the US FDA Guidelines for Bioavailability & Bioequivalence Studies, is an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects will be evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. To date, all subjects have been dosed with no significant adverse events. Full completion of the study is expected in Third Quarter 2023 and results will be used to determine L-130 dose levels for a planned Phase 2a study in chronic cluster headaches. Often said to be the most painful of all headaches, cluster headaches are a primary headache disorder and the most common of the group of headache disorders called trigeminal autonomic cephalalgias. The term cluster headaches comes from the fact that these attacks occur in groups, or "clusters." During a cluster cycle, brief, exceptionally severe headache attacks recur between 1-8 times per day. Cluster cycles can last for weeks or months and are usually separated by remission periods, or periods of headache freedom, which usually last months or years. People who experience chronic cluster headache have no remission periods, or the remissions last less than a month at a time. 공지 • Jun 08
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer Lobe Sciences Ltd. announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with sickle cell anemia. Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia. Phillips will report directly to Chairman and Chief Executive Officer Philip J. Young. In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company. For the past 10 years of his 25 year career, Baxter has served as an executive officer, including CEO, of several multi-national biopharmaceutical companies including Cambridge Allergy (UK), Neurogastrx (US) and Armata Pharma (AmpliPhi, multi-national). Mr. Phillips has a successful history of acquiring and launching commercial products, leading multiple public and private financing campaigns, establishing cGMP manufacturing, and licensing product portfolios of commercial and development-stage programs. Mr. Phillips began his career as a research scientist with Insmed (INSM) where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College. 공지 • Dec 01
Lobe Sciences Ltd. Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130 Lobe Sciences Ltd. announced an update for its clinical development plans for its proprietary Psilocin based compound L-130. L-130 is regulated as a Schedule 1 substance in the United States and most countries around the world. The Company has received regulatory clearance to import L-130. Initial Phase 1 clinical trials will utilize Clearway Global's network of contract research organizations and believe that first subject will enter the first trial in December and topline data will be available for review early in the first quarter of 2023. Data will include safety and pharmacokinetic characteristics of L-130 and psychedelic properties, if any. A second Phase 1 trial is scheduled for the first quarter of 2023 and will accurately assess the therapeutic window for the subsequent Phase 2a trial planned to follow. As previously announced, the Company has partnered with iNGENu CRO, a contract research organization to finalize and conduct the Phase 2a protocol in Australia. Company expect to dose first patient in Phase 2 trial in second quarter/third quarter 2023. Company will provide updates as finalize plans for this important program. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Member of Scientific Advisory Board Mark Geyer is the most experienced director on the board, commencing their role in 2020. Independent Director Mike Petter was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공지 • Oct 06
Lobe Sciences Ltd. Appoints Baxter F. Phillips III to the Board of Directors Lobe Sciences Ltd. announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry. As a member of the Company's Board of Directors, Mr. Phillips will also serve as the Chairman of the Audit Committees. Most recently, Baxter was Chief Executive Officer of UK based Camallergy where he continues to serves as an independent director. Prior to Camllergy, Mr. Phillips was CEO of Neurogastrx, where he successfully led the company to its transformational $45 million Series A financing. Prior to Neurogastrx, Mr. Phillips served as Chief Business Officer of AmpliPhi Biosciences (now Armata Pharmaceuticals: ARMP), where he played a pivotal role in establishing manufacturing, leading multiple financing campaigns and navigating the company to its NYSE listing. Prior to AmpliPhi, Baxter's leadership appointments included Depomed, where he was responsible for licensing the product portfolio of development-stage and marketed products on a global basis, and Osteologix, where he successfully concluded a global licensing transaction with a multinational pharmaceutical company. Mr. Phillips began his career as a research scientist with Insmed (INSM). where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College. 공지 • Sep 09
Lobe Sciences Ltd. announced that it has received CAD 1.41314 million in funding Lobe Sciences Ltd. announced that it has closed a non-brokered private placement of 28,262,800 units at a price of CAD 0.05 per unit for gross proceeds of CAD 1,413,140 on September 8, 2022. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of CAD 0.05 per share until September 8, 2025, subject to an accelerated expiry if, on any ten consecutive trading days occurring after four months and one day has elapsed following September 8, 2022, the closing price of the share as quoted on the Canadian Securities Exchange is greater than CAD 0.05 per share. The company paid Peak Asset Management of Melbourne Australia a finder’s fee equal to 8% of funds raised in Australia in connection with the transaction. The total finders' fee was CAD 65,640 which was settled through the issuance of 1,312,800 units. All shares and warrants comprising the units issued pursuant to the transaction are subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. Board Change • Apr 27
Less than half of directors are independent There are 12 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Member of Strategic Advisory Board Sean-Robbie Campbell is the most experienced director on the board, commencing their role in 2019. Independent Director Mike Petter was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공지 • Mar 05
Lobe Sciences Ltd. Appoints Bart Oates Esq. to Advisory Board Lobe Sciences Ltd. appointed Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board. Bart Oates Esq. is a three-time Superbowl Champion, who graduated magna cum laude with a Juris Doctor degree from Seton Hall during his off season. Prior to his NFL career, he earned a BS in Accounting from the Marriott School of Business at BYU and was inducted into their athletic Hall of Fame in 1992. Bart was selected to five Pro Bowls during his NFL career and to the UPI All-NFC team three times. Bart is now the President of the NFL Alumni Association which offers former players a diverse package of medical, business, and legal services to help keep them and their families healthy, productive, and connected to their former teammates. Is New 90 Day High Low • Feb 23
New 90-day high: CA$0.27 The company is up 440% from its price of CA$0.05 on 24 November 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Real Estate industry, which is up 10.0% over the same period. Reported Earnings • Jan 25
First quarter 2021 earnings released: CA$0.009 loss per share First quarter 2021 results: Net loss: CA$1.25m (loss widened 82% from 1Q 2020). 공지 • Jan 20
Lobe Sciences Ltd Announces the Appointment of Philip J. Young as Corporate Secretary and A Director Lobe Sciences Ltd. announced the appointment of Mr. Philip J. Young as Corporate Secretary and a director of the Company, effective January 15, 2021. Philip Young is an accomplished CEO and innovative professional with 25 years of expertise in senior executive management and board roles, with significant mergers and acquisitions and equity financing experience. He has a proven track record in the biotech, medtech and pharmaceutical industries with expertise in dealing with FDA/regulatory frameworks as well as new device and therapeutics development. From 2015 until 2019, Mr. Young was the Founder, Chairman, and CEO of Exactus Inc. (Exactus). Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc.). He was also previously the President, CEO and a director of Osteologix Inc., where he was responsible for directing and managing all facets of the global pharmaceutical development company. He is the former Chief Business Officer and Executive Vice President of Insmed Inc., where he directed all financing, corporate and commercial communications activities. Prior thereto, he was the Vice President and General Manager of Neurex Corp. 공지 • Jan 19
Lobe Sciences Ltd. Announces Executive Changes Lobe Sciences Ltd. announced the appointment of Mr. Philip J. Young as Chief Executive Officer, effective January 15, 2021. Mr. Young replaces Thomas Baird, who resigned as CEO as of the same date. Philip Young is an accomplished CEO and innovative professional with 25 years of expertise in senior executive management and board roles, with significant mergers and acquisitions and equity financing experience. He has a proven track record in the biotech, medtech and pharmaceutical industries with expertise in dealing with FDA/regulatory frameworks as well as new device and therapeutics development. From 2015 until 2019, Mr. Young was the Founder, Chairman, and CEO of Exactus Inc. (Exactus). Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc.). He was also previously the President, CEO and a director of Osteologix Inc., where he was responsible for directing and managing all facets of the global pharmaceutical development company. He is the former Chief Business Officer and Executive Vice President of Insmed Inc., where he directed all financing, corporate and commercial communications activities. Prior thereto, he was the Vice President and General Manager of Neurex Corp. 공지 • Jan 16
Lobe Sciences Ltd., Annual General Meeting, Mar 15, 2021 Lobe Sciences Ltd., Annual General Meeting, Mar 15, 2021. 공지 • Jan 09
Lobe Sciences Ltd. Announces Changes to Board of Directors Lobe Sciences Ltd. announce the appointment of Mr. Michael Petter as an independent director to the Company's Board of Directors, effective immediately. Mr. Petter replaces Thomas Baird, who resigned from the Company's Board of Directors effective 08 January 2021, but still remains CEO of the Company. Michael Petter is an accomplished leader and entrepreneur with significant experience in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mr. Petter has significant psychedelic and cannabis industry expertise. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance and logistics. 공지 • Dec 17
Lobe Sciences Ltd. Announces Appointment of Jonathan Gilbert as Executive Chairman of the Board of Directors Lobe Sciences Ltd. announced that the appointment of Mr. Jonathan Gilbert as executive chairman of the board of directors. Jonathan Gilbert has over 20 years of leadership, capital raising and public markets expertise. He is considered one of the leaders in both the cannabis and emerging psychedelic sectors, having successfully co-founded and run several companies, leading them to successful M&A transactions. Jonathan originally joined the company's board of directors in July, 2020 in conjunction with the acquisition of Eleusian Biosciences Corp. which he was co-founder, CEO and director. He is an accomplished leader and business executive with several successful exits in the psychedelics and cannabis sector. Previously, he was the co-founder, CEO and director of SOL Global Investments Corp. (formerly Scythian Biosciences Corp.), a publicly traded research and development company focusing on the prevention and treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. He was also founder, CEO and a director of Tassili Life Sciences Corp., which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Gilbert was also executive chairman of Exactus Inc., an OTC listed company focused on farming and production of hemp to be manufactured into cannabidiol (CBD) related products. 공지 • Dec 16
Lobe Sciences Ltd. announced that it expects to receive CAD 2 million in funding Lobe Sciences Ltd. (CNSX:LOBE) announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.10 per unit for gross proceeds of up to CAD 2,000,000 on December 14, 2020. Each unit will consist of one common share and one share purchase warrant. Each whole warrant will entitle the subscriber to acquire one additional share at a price of CAD 0.25 per warrant for two years from the applicable closing date, subject to an accelerated expiry provision described herein. If on any 10 consecutive trading days occurring after four months and one day has elapsed following the final closing date of the offering, the closing price of the shares as quoted on the Canadian Securities Exchange is greater than CAD 0.35 per share, company may provide notice in writing to the holders of the warrants by issuance of a news release that the expiry date of the warrants will be accelerated to the 30th day. The closing of the transaction is subject to a number of conditions, including but not limited to, approval by the Canadian Securities Exchange. The transaction may be closed in one or more tranches. The company will pay finder’s fees. The shares and warrants comprising the units and the finders warrants issued pursuant to the transaction will be subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. Is New 90 Day High Low • Dec 15
New 90-day high: CA$0.21 The company is up 282% from its price of CA$0.055 on 15 September 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Real Estate industry, which is up 1.0% over the same period. 공지 • Dec 02
Ionic Brands Corp. (CNSX:IONC) entered into a non-binding letter of intent to acquire Certain assets of Lobe Sciences Ltd. for CAD 23 million. Ionic Brands Corp. (CNSX:IONC) entered into a non-binding letter of intent to acquire Certain assets of Lobe Sciences Ltd. for CAD 23 million on December 1, 2020. The sale price for the Assets shall be a minimum of CAD 23 million, payable through the issuance of Ionic post-consolidation common shares. Following the closing of the Transaction, it is expected that the Lobe will own approximately 49% of Ionic’s common shares. Following the closing of the Transaction, Ionic’s board of directors is expected to be comprised of five (5) members and Lobe will have the right to appoint two (2) directors to the Ionic board. The Transaction is subject to several closing conditions: (i) satisfactory due diligence by both Ionic and Lobe; (ii) completion of a definitive agreement with binding terms and conditions for the Transaction, including finalization of the specific Assets that will be sold and certain Cowlitz assets that may be retained by Lobe; (iii) all respective directors and officers of Lobe and Ionic entering into support agreements for the Transaction; (iv) approval by the boards of directors of both Lobe and Ionic; (v) the completion of a share consolidation by Ionic on a minimum of one new Ionic common share for every four and a half (4.5) old Ionic common shares; (vi) the conversion of all Ionic debentures into a secured equity or a similar instrument; (vii) completion of a concurrent financing by Ionic for gross proceeds of at least US$2 million; (viii) Ionic having all cease trade orders issued against it lifted(2); (ix) Ionic applying to the CSE for requalification and qualifying for listing and resumption of trading(2); and (xviii) the receipt of all required shareholder and regulatory approvals, including the approval of the CSE. The proposed transaction with Ionic is accretive to both parties. 공지 • Oct 08
Greenstar Biosciences Corp. Announces Launch of Science Advisory Board and Appointment of Dr. Mark A. Geyer as Board Member GreenStar Biosciences Corp. announced the formation and launch of its science advisory board and the appointment of its first distinguished board member, Dr. Mark Geyer, Professor Emeritus at University of California San Diego, who is a recognized pioneer in the psychedelics industry. Dr. Mark A. Geyer Ph.D. is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego ("UCSD"). He directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. He is also on the scientific advisory board of the Beckley Foundation. 공지 • Oct 06
Greenstar Biosciences Corp. announced that it has received CAD 1.698247 million in funding On October 5, 2020, Greenstar Biosciences Corp. (CNSX:GSTR) closed the transaction. The company received CAD 1,698,246 in the transaction. The company issued 10,831,234 units and received CAD 866,498.72 in its second and final tranche. The company paid Peak Asset Management an aggregate finder' fees of CAD 129,639.90, of which CAD 29,639.90 was settled through the issuance of 370,498 Units, and 1,620,498 finders warrants. Each finders warrant is exercisable into one share at an exercise price of CAD 0.20 until October 2, 2023. 공지 • Aug 18
Greenstar Biosciences Corp. announced that it expects to receive CAD 4 million in funding Greenstar Biosciences Corp. (CNSX:GSTR) announced a private placement of up to 50,000,000 units at a price of CAD 0.08 per unit for gross proceeds of up to CAD 4,000,000 on August 17, 2020. Each unit will consist of one common share and one-half of one share purchase warrant. Each whole warrant will entitle the subscriber to acquire one additional share at a price of CAD 0.20 per warrant until March 31, 2022. The closing of the transaction is subject to a number of conditions, including but not limited to, approval by the Canadian Securities Exchange. The transaction may be closed in one or more tranches. The company will pay finders fees of up to 8% of the gross proceeds in cash and issue 8% finder warrants of the units to Peak Asset Management and may engage other finders to assist with the transaction. Each finders warrant will be exercisable into one share at an exercise price of CAD 0.20 until March 31, 2022. The shares and warrants comprising the units and the finders warrants issued pursuant to the transaction will be subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. 공지 • Jul 24
Greenstar Biosciences Corp. announced that it has received CAD 0.585 million in funding On July 23, 2020, Greenstar Biosciences Corp. (CNSX:GSTR) closed the transaction. 공지 • Jul 21
Greenstar Biosciences Corp. announced that it expects to receive CAD 0.585 million in funding Greenstar Biosciences Corp. (CNSX:GSTR) announced a non-brokered private placement to issue 11,700,000 common shares at issue price of CAD 0.05 per share for gross proceeds of CAD 585,000 on July 20, 2020. The company will not pay any finders fees in relation to the transaction. The securities issued in the transaction is subject to a statutory hold period of four month and one day from the closing of the transaction. 공지 • Jun 17
Greenstar Biosciences Corp. (CNSX:GSTR) signed a non-binding letter of intent to acquire Eleusian Biosciences Corp. for CAD 3.6 million. Greenstar Biosciences Corp. (CNSX:GSTR) signed a non-binding letter of intent to acquire Eleusian Biosciences Corp. for CAD 3.6 million on June 12, 2020. Pursuant to the Agreement, GreenStar will issue Eleusian shareholders a total of 60 million common shares of GreenStar and will issue an aggregate of 250,109 stock options to certain Eleusian personnel. All GreenStar Shares to be issued will be subject to voluntary pooling arrangements, pursuant to which 25% of the GreenStar Shares will be released on the closing date of the Transaction and further 25% releases will occur every three months thereafter.
Maghsoud Dariani will join GreenStar as its Chief Scientific Officer, Eleusian will have the right to appoint one nominee to the GreenStar board of directors. The Transaction is subject to a number of conditions, including but not limited to, final due diligence by the parties, execution of a definitive acquisition agreement and receipt of applicable corporate and regulatory approvals. 
